the value of subcutaneous alnuctamab for the treatment of r/r multiple myeloma
Published 1 year ago • 62 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
2:46
subcutaneous alnuctamab in patients with r/r multiple myeloma: the results of a phase i trial
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
2:01
ctcs as a biomarker of tumor burden in multiple myeloma
-
0:59
defining the origins of multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
2:09
integrating novel agents into the treatment of multiple myeloma
-
0:54
azintuxizumab vedotin for r/r multiple myeloma
-
21:38
drawing the line: the rationale behind blood tube collection order
-
5:19
the current treatment landscape for multiple myeloma and trials investigating novel combinations
-
1:37
predictors of unsustained mrd negativity in transplant-eligible patients with multiple myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
1:01
car-t: myeloma toxicities
-
2:42
the value of circulating tumor cells for the staging of patients with ndmm
-
2:20
promising novel treatments in multiple myeloma
-
2:20
ultra high-risk myeloma
-
2:56
novel drugs for myeloma thromboprophylaxis
-
2:53
key multiple myeloma data from asco 2020
-
5:40
positioning immunotherapies in the changing paradigm of myeloma treatment
-
2:46
managing patients with high-risk myeloma
-
2:32
refining the current staging system for multiple myeloma